title: Keeping the ball in bounds.
abstract: The notion of 'one drug, many uses' may drive sales and give hope to sick patients who are willing to try anything. But the government's crackdown on off-label promotion has biotech companies carefully watching their step, even as CMS policy appears to encourage scientific study of off-label use.
authors: John
authors: J
authors: Carroll